Grade 3-5 adverse events were comparable between both treatment groups. Evidence Rating Level: 1 (Excellent) Study Rundown: ...

Astellas Pharma Ltd. today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted authorization for PADCEV™ (enfortumab vedotin, an antibody-drug conjugate [ADC]) in ...

This study is looking at an immunotherapy treatment called V940 (mRNA-4157) with pembrolizumab to treat melanoma.

In the randomized, double-blind, phase 3 study, experts explored treatment with neoadjuvant pembrolizumab (Keytruda) plus chemotherapy, followed by adjuvant pembrolizumab, in patients aged 18 years ...

First targeted treatment to reduce the risk of ALK positive lung cancer returning after complete tumour removal recommended ...

Combined company will operate as TuHURA Biosciences, Inc. and advance pipeline of novel technologies to overcome resistance to cancer ...

Last week, the biotech sector was in focus, with regular pipeline and regulatory updates. Vanda Pharmaceuticals Inc. VNDA was in the spotlight after it rejected a second takeover bid by Cycle Group.

DelveInsight's 'Antibody-drug Conjugates in Oncology Competitive Landscape – 2024' report provides comprehensive global coverage of ...

Combined company will operate as TuHURA Biosciences, Inc. and advance pipeline of novel technologies to overcome resistance to cancer immunotherapyLead program entering single Phase 3 accelerated appr ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

mRNA vaccines, pivotal in the fight against COVID-19, are now emerging as a promising innovation in cancer treatment. As ...